
Amber D. Steele
Examiner (ID: 2430, Phone: (571)272-5538 , Office: P/1676 )
| Most Active Art Unit | 1658 |
| Art Unit(s) | 1654, 1639, 1658, 1676 |
| Total Applications | 1302 |
| Issued Applications | 628 |
| Pending Applications | 166 |
| Abandoned Applications | 538 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20795422
[patent_doc_number] => 20260176321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-06-25
[patent_title] => PROCESSES AND INTERMEDIATES FOR PREPARING TIRZEPATIDE
[patent_app_type] => utility
[patent_app_number] => 19/351688
[patent_app_country] => US
[patent_app_date] => 2025-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8583
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19351688
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/351688 | PROCESSES AND INTERMEDIATES FOR PREPARING TIRZEPATIDE | Oct 6, 2025 | Pending |
Array
(
[id] => 20288367
[patent_doc_number] => 20250313610
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-09
[patent_title] => USE OF APOLIPOPROTEIN H IN MANUFACTURE OF MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF FATTY LIVER DISEASE AND RELATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 19/241432
[patent_app_country] => US
[patent_app_date] => 2025-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 447
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19241432
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/241432 | USE OF APOLIPOPROTEIN H IN MANUFACTURE OF MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF FATTY LIVER DISEASE AND RELATED DISEASES | Jun 17, 2025 | Pending |
Array
(
[id] => 20694021
[patent_doc_number] => 20260125427
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-05-07
[patent_title] => METHOD FOR PREVENTING FORMATION OF AMYLOID B AGGREGATION AND TREATING AMYLOIDOSIS BY USING SYNTHETIC PEPTIDE
[patent_app_type] => utility
[patent_app_number] => 19/209235
[patent_app_country] => US
[patent_app_date] => 2025-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19209235
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/209235 | METHOD FOR PREVENTING FORMATION OF AMYLOID B AGGREGATION AND TREATING AMYLOIDOSIS BY USING SYNTHETIC PEPTIDE | May 14, 2025 | Pending |
Array
(
[id] => 20279378
[patent_doc_number] => 20250304620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-02
[patent_title] => ANTIMICROBIAL PEPTIDE AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 19/192339
[patent_app_country] => US
[patent_app_date] => 2025-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5681
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19192339
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/192339 | ANTIMICROBIAL PEPTIDE AND APPLICATION THEREOF | Apr 28, 2025 | Abandoned |
Array
(
[id] => 20041240
[patent_doc_number] => 20250179462
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-05
[patent_title] => FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
[patent_app_type] => utility
[patent_app_number] => 19/024178
[patent_app_country] => US
[patent_app_date] => 2025-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6961
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 137
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19024178
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/024178 | FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION | Jan 15, 2025 | Abandoned |
Array
(
[id] => 20143977
[patent_doc_number] => 12378304
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-05
[patent_title] => Therapeutic polypeptide
[patent_app_type] => utility
[patent_app_number] => 18/903864
[patent_app_country] => US
[patent_app_date] => 2024-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 25
[patent_no_of_words] => 17643
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18903864
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/903864 | Therapeutic polypeptide | Sep 30, 2024 | Issued |
Array
(
[id] => 19785572
[patent_doc_number] => 20250059251
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-20
[patent_title] => INCRETIN ANALOGS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/893357
[patent_app_country] => US
[patent_app_date] => 2024-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10238
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18893357
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/893357 | Incretin analogs and uses thereof | Sep 22, 2024 | Issued |
Array
(
[id] => 20402254
[patent_doc_number] => 12492223
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-09
[patent_title] => Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/829844
[patent_app_country] => US
[patent_app_date] => 2024-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 4
[patent_no_of_words] => 15309
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18829844
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/829844 | Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof | Sep 9, 2024 | Issued |
Array
(
[id] => 19931741
[patent_doc_number] => 12304938
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => Processes and intermediates for preparing tirzepatide
[patent_app_type] => utility
[patent_app_number] => 18/806394
[patent_app_country] => US
[patent_app_date] => 2024-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 8577
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18806394
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/806394 | Processes and intermediates for preparing tirzepatide | Aug 14, 2024 | Issued |
Array
(
[id] => 19745645
[patent_doc_number] => 20250034210
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/743018
[patent_app_country] => US
[patent_app_date] => 2024-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40085
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18743018
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/743018 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Jun 12, 2024 | Pending |
Array
(
[id] => 19709260
[patent_doc_number] => 20250019402
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => PHARMACOKINETICS AND CHOLECYSTOKININ-2 RECEPTOR (CCK2R) TARGETING FOR DIAGNOSIS AND THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/742460
[patent_app_country] => US
[patent_app_date] => 2024-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15066
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18742460
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/742460 | PHARMACOKINETICS AND CHOLECYSTOKININ-2 RECEPTOR (CCK2R) TARGETING FOR DIAGNOSIS AND THERAPY | Jun 12, 2024 | Pending |
Array
(
[id] => 19541755
[patent_doc_number] => 20240358791
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => PEPTIDES AND METHODS OF TREATING DYSTROPHY-RELATED DISORDERS USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/680874
[patent_app_country] => US
[patent_app_date] => 2024-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34260
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18680874
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/680874 | PEPTIDES AND METHODS OF TREATING DYSTROPHY-RELATED DISORDERS USING THE SAME | May 30, 2024 | Pending |
Array
(
[id] => 19641406
[patent_doc_number] => 20240415926
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-19
[patent_title] => GENE PPARalpha FOR IMPROVING DISEASE RESISTANCE OF HALF-SMOOTH TONGUE SOLE CYNOGLOSSUS SEMILAEVIS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/611711
[patent_app_country] => US
[patent_app_date] => 2024-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2448
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611711
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/611711 | GENE PPARalpha FOR IMPROVING DISEASE RESISTANCE OF HALF-SMOOTH TONGUE SOLE CYNOGLOSSUS SEMILAEVIS AND USE THEREOF | Mar 20, 2024 | Abandoned |
Array
(
[id] => 20256125
[patent_doc_number] => 12428468
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-30
[patent_title] => Human collagen 17-type polypeptide, production method therefor and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/612612
[patent_app_country] => US
[patent_app_date] => 2024-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 9
[patent_no_of_words] => 4463
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18612612
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/612612 | Human collagen 17-type polypeptide, production method therefor and use thereof | Mar 20, 2024 | Issued |
Array
(
[id] => 20256126
[patent_doc_number] => 12428469
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-30
[patent_title] => Human collagen 17-type polypeptide, production method therefor and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/612627
[patent_app_country] => US
[patent_app_date] => 2024-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 9
[patent_no_of_words] => 3768
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18612627
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/612627 | Human collagen 17-type polypeptide, production method therefor and use thereof | Mar 20, 2024 | Issued |
Array
(
[id] => 19769985
[patent_doc_number] => 20250051411
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => COMPOSITIONS AND METHODS FOR USING ACTIN-BASED PEPTIDES TO MODULATE CELLULAR BIOACTIVITY AND CELLULAR SUSCEPTIBILITY TO INTRACELLULAR PATHOGENS
[patent_app_type] => utility
[patent_app_number] => 18/602390
[patent_app_country] => US
[patent_app_date] => 2024-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14869
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18602390
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/602390 | COMPOSITIONS AND METHODS FOR USING ACTIN-BASED PEPTIDES TO MODULATE CELLULAR BIOACTIVITY AND CELLULAR SUSCEPTIBILITY TO INTRACELLULAR PATHOGENS | Mar 11, 2024 | Pending |
Array
(
[id] => 20645815
[patent_doc_number] => 12600749
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-14
[patent_title] => Compstatin analogues and their medical uses
[patent_app_type] => utility
[patent_app_number] => 18/601031
[patent_app_country] => US
[patent_app_date] => 2024-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 6
[patent_no_of_words] => 17114
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 256
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18601031
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/601031 | Compstatin analogues and their medical uses | Mar 10, 2024 | Issued |
Array
(
[id] => 19745980
[patent_doc_number] => 20250034545
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY
[patent_app_type] => utility
[patent_app_number] => 18/590842
[patent_app_country] => US
[patent_app_date] => 2024-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5854
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18590842
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/590842 | MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY | Feb 27, 2024 | Abandoned |
Array
(
[id] => 20372481
[patent_doc_number] => 12479905
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-25
[patent_title] => Peptide used for immunotherapeutics
[patent_app_type] => utility
[patent_app_number] => 18/584321
[patent_app_country] => US
[patent_app_date] => 2024-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 40477
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18584321
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/584321 | Peptide used for immunotherapeutics | Feb 21, 2024 | Issued |
Array
(
[id] => 20076285
[patent_doc_number] => 12350320
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-08
[patent_title] => Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and pharmaceutically acceptable salts of amylin analogs, and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/444501
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 55
[patent_figures_cnt] => 60
[patent_no_of_words] => 73694
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18444501
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/444501 | Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and pharmaceutically acceptable salts of amylin analogs, and uses thereof | Feb 15, 2024 | Issued |